Mutation in KRAS
KRAS G12C
253 active trials select patients by KRAS G12C or a broader group, and 145 of them are recruiting. 4 FDA and 2 EU approvals name it.
Trials as of 2026-10-27. Seen most often in NSCLC, colorectal, pancreatic.
Approved therapies
Approvals in the United States (FDA) and the European Union (EMA), one row per drug, regimen and tumour type. Open a row for the exact indication and source.
| Therapy | Tumour | United States | European Union |
|---|---|---|---|
adagrasib
|
NSCLC | Approved 2022 accelerated | Approved 2024 conditional |
sotorasib
|
NSCLC | Approved 2021 accelerated | Approved 2022 conditional |
sotorasib with panitumumab
|
colorectal | Approved 2025 | Not approved |
avutometinib + defactinib
|
low-grade serous ovarian | Approved 2025 accelerated | Not approved |
adagrasib with cetuximab
|
colorectal | Withdrawn approved 2024 | Not approved |
Companies
Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.
- MSD (Merck & Co.) 11
- Bristol Myers Squibb 9
- Roche 8
- Revolution Medicines 7
- Allist Pharmaceuticals 6
- Eli Lilly 6
- Amgen 5
- Hansoh Pharma 4
- AstraZeneca 3
- Shandong Suncadia Medicine 3
- Genfleet Therapeutics (Shanghai) 3
- Jiangsu Hengrui 3
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 3
- InxMed (Shanghai) 2
- Jemincare 2
Trials
Matched automatically from registry text, so a few trials may only mention KRAS G12C rather than require it. Check the quoted criterion, and the registry entry before relying on a match.
253 of 542 trials shown
-
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
HRS-7058Fulzerasib TabletsGarsorasib TabletsGlecirasib Citrate Tablets
…enter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Stand…
KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
-
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Sosimerasib in combination with IN10018Tislelizumab + Carboplatin + Pemetrexed
Has KRAS G12C mutation confirmed by central laboratory.
NSCLC
-
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
DivarasibPembrolizumabNivolumab
Documentation of the presence of a KRAS G12C mutation
Non-small Cell Lung Cancer
-
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
HS-10370AdebrelimabCisplatinCarboplatinPemetrexedTislelizumab
Documentation of the presence of a KRAS G12C mutation
Carcinoma, Non-Small-Cell Lung
-
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
CalderasibDurvalumab
…rvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platin…
Non-small Cell Lung Cancer
-
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
CalderasibMK-3475A
Tumor tissue shows the presence of Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
Non-small Cell Lung Cancer
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
CalderasibOxaliplatinLeucovorin/levofolinate calcium5-FluorouracilCetuximabBevacizumab
Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
Colon Adenocarcinoma, Rectal Adenocarcinoma
-
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
CalderasibPembrolizumab (+) Berahyaluronidase alfaPemetrexedCisplatinCarboplatin
…inum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Non-small Cell Lung Cancer
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Adagrasib FDA EUPembrolizumabCarboplatinPemetrexedCisplatin
…istologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).
Carcinoma, Non-Small-Cell Lung
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
DivarasibPembrolizumabPemetrexedCarboplatinCisplatin
Documentation of the presence of a KRAS G12C mutation
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
-
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
JMKX001899Docetaxel
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
NSCLC (Non-small Cell Lung Cancer)
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
OlomorasibPembrolizumabDurvalumab
Must have disease with evidence of KRAS G12C mutation.
Carcinoma, Non-Small-Cell Lung
-
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
IN10018 in combination with D-1553anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
Has KRAS G12C mutation confirmed by central laboratory
Non-Small Cell Lung Cancer
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
FOLFIRI RegimenSotorasib FDA EUPanitumumabBevacizumab-awwb
Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
Metastatic Colorectal Cancer
-
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE2101Docetaxel
KRAS G12C and BRAF mutations) after Sponsor' agreement.
Patients With Non-Small Cell Lung Cancer
-
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
DivarasibSotorasib FDA EUAdagrasib FDA EU
Documentation of the presence of a KRAS G12C mutation
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
-
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
CalderasibPembrolizumab
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum…
Non-small Cell Lung Cancer
-
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
JAB-21822TislelizumabJAB-3312PemetrexedCarboplatin
G12C mutation confirmed by the central lab
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
-
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
D-1553 TabletDocetaxel injection
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior S…
Status may be outdated, last updated 2024-04-26Non Small Cell Lung Cancer
-
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
LY3537982PembrolizumabCisplatinCarboplatinPemetrexed
Must have disease with evidence of KRAS G12C mutation.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
-
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
JDQ443docetaxel
Participant has a KRAS G12C mutation present in tumor tissue or plasma prior to enrollment, as determined by a Novart…
Non-Small Cell Lung Cancer
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
MRTX849CetuximabmFOLFOX6 RegimenFOLFIRI Regimen
Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
-
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
MRTX849 FDA EUDocetaxel
Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Adagrasib FDA EUAdagrasib FDA EUAdagrasib FDA EUAdagrasib FDA EUPembrolizumab
Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
-
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
BLU-924
… non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribon…
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
-
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
…on 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.
Lung Cancer (NSCLC)
-
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
VebreltinibChemotherapy
…negative EGFR mutation, negative ALK rearrangement, negative ROS1 rearrangement, negative KRAS G12C mutation, and negative MET exon 14 skipping mutation.
Lung Neoplasms
-
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
KRAS G12C
Lung Adenocarcinoma
-
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Sotorasib FDA EUTrastuzumab Deruxtecan
…must have histologically or cytologically documented locally advanced or metastatic KRAS\^G12C-mutant NSCLC that has previously been treated with a KRAS\^G12C inhibitor AND an immune c…
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
-
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
HRS-7058
…y of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.
Pancreatic Cancer
-
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Adagrasib FDA EURecombinant Human EGF-rP64K/Montanide ISA 51 VaccineSotorasib FDA EU
Documented KRAS G12C mutation.
Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
-
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
OlomorasibCetuximabOxaliplatinLeucovorin/levofolinate calcium5-fluorouracil
Must have disease with evidence of KRAS G12C mutation
Colorectal Neoplasms
-
A 2-part Phase 1/2 Open-label Trial on ODM-212
ODM-212Ipilimumab and nivolumabGemcitabine and nab-paclitaxelsotorasib FDA EU
…ically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C mutation, confirmed using a validated test, who have documented progression on a prior KR…
Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
-
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
MK-1084Patritumab deruxtecanSacituzumab tirumotecanCetuximabRescue Medications
…of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations
Lung Neoplasm Malignant
-
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
fulzerasib; cetuximab N01
PMMR/MSS, KRAS G12C mutation, and both NRAS and BRAF wild-type
Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01
-
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
KRAS Neoantigen Nanovaccine
…arbor at least one of the following KRAS hotspot mutations: G12D, G12V, G12R, G12A, G12S, G12C, or G13D.
Colorectal Cancer, Pancreatic Cancer
-
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
GlecirasibIvonescimab
KRAS G12C mutation confirmed by validated testing.
NSCLC Stage IV, KRAS G12C
-
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
fulzerasib
All subjects must have a written test report before enrollment to prove the presence of KRAS G12C mutation
Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
-
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
GarsorasibIvonescimab Combined With ChemotherapyGarsorasibIvonescimab
Mutation Status: KRAS G12C mutation positivity must be confirmed by next-generation sequencing (NGS) or polymerase c…
Lung Cancer (NSCLC), KRAS G12C Lung Cancer
-
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
AmivantamabOlomorasib
…t must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment.
Carcinoma, Non-Small-Cell Lung
-
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BL-B01D1Glecirasib
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
-
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
SY-5933CT-707
KRAS (G12C) mutation positive.
Advanced Solid Tumor
-
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
JS207PemetrexedCarboplatin or cisplatinJS212
… ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon skipping mutation, RET fusion, KRAS G12C mutation, HER-2 mutation, EGFR 20 exon insertion mutation.
Non-squamous Non-small Cell Lung Cancer
-
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
IBI351 combined with cetuximab β
Documented KRAS G12C mutation confirmed by a written report from a certified laboratory.
Lung Cancer (Non-Small Cell)
-
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
ABT-301TislelizumabBevacizumab (Avastin)
NOTE: Participants with BRAF V600E, HER2 amplification/ mutation, KRAS G12C mutation, NTRK gene fusion, RET fusion, may or may not have received relevant targeted th…
Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
-
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Garsorasib, Benmelstobart, AnlotinibBenmelstobart, AnlotinibGarsorasib, Cetuximab Beta Injection
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Local Advanced or Metastatic NSCLC
-
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
IBI351+AK112
All subjects must have a written test report before enrollment to prove the presence of KRAS G12C mutation
KRAS G12C Lung Cancer
-
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
Administration of experimental treatment association (sotorasib, panitumumab 5FU) FDA EU
Proven KRAS G12C mutation as locally assessed by means of an IVDR-compliant test
Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
-
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
ABSK043 in combination with Glecirasib
Tumor tissue or blood test report confirmed KRASG12C mutation.
Non-Small Cell Lung Cancer
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
MK-1084PembrolizumabCetuximabSacituzumab tirumotecan (sac-TMT)Rescue medication
…cid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
Malignant Neoplasm
-
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
IBI351, cetuximab β combined with FOLFIRI
There is a written test report proving the presence of KRASG12C mutation: PCR method or NGS method detection clearly indicates KRASG12C mutation 4.
Colorectal Cancer Metastatic, KRAS G12C Mutation
-
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
CalderasibCetuximab
Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation
Neoplasm Malignant
-
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
GH21，D-1553
…or cytologically confirmed locally advanced or metastatic non-small cell lung cancer with KRASG12C mutation who have failed standard therapy or no standard therapy and have been treated wi…
Locally Advanced or Metastatic Solid Tumors
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
PanitumumabSotorasib FDA EU
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
-
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
GH21D-1553
KRAS G12C mutant advanced solid tumor;
Status may be outdated, last updated 2024-07-08Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
-
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Sotorasib FDA EU
KRAS G12C mutation on prior tumor biopsy or cell-free DNA (cfDNA) testing
Non Small Lung Cancer
-
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
FMC-376
… or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
-
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RMC-6291RMC-6236PembrolizumabCisplatinCarboplatinPemetrexed
Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Adagrasib FDA EU
…CLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation.
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
CetuximabCemiplimabAdagrasib FDA EU
…y confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of therapy
Metastatic Colorectal Cancer, KRAS G12C Mutations
-
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Adagrasib FDA EU
Known to have a KRAS G12C mutation.
Non Small Cell Lung Cancer, NSCLC, KRAS G12C
-
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
ELI-002 7P
KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
-
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ElironrasibDaraxonrasib
Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
-
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3S-002D3S-001
…st have documented Kirsten rat sarcoma viral oncogene (KRAS) p. glycine 12 to cysteine (p.G12C) mutation identified within the last 5 years by a local test on tumor tissue or blood.
Advanced Solid Tumors With MAPK Pathway Mutations
-
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
Adagrasib FDA EU
KRASG12C-mutation by local testing (by tissue or ctDNA).
NSCLC Stage IV, KRAS P.G12C
-
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
DivarasibPembrolizumabCarboplatinCisplatinPemetrexed
…ipants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-Small Cell Lung Cancer
-
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Trastuzumab deruxtecanDurvalumabPanitumumabBotensilimabBalstilimabSotorasib FDA EU
COHORT 8: pMMR/MSS status and KRAS G12C mutation, absence of HER2 overexpression/amplification and wild-type status for BRAF.
Colorectal Cancer, Resectable Colorectal Carcinoma
-
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
S241656FOLFOX6/FOLFOX7FOLFIRICetuximabPanitumumabGemcitabine
Part 2A4: Advanced/metastatic NSCLC with a KRAS G12C mutation
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
-
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
JAB-21822
Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic rea…
KRAS P.G12C, Pancreatic Cancer, Solid Tumor
-
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
JAB 21822
Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.
Non-small Cell Lung Cancer
-
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
JAB-21822JAB-3312
…or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or in…
KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
-
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3S-001PembrolizumabCisplatinCarboplatinPemetrexedCetuximab
Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.
KRAS P.G12C
-
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
JAB-21822Cetuximab
… colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation
Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
-
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Sotorasib 120Mg Tab FDA EU
…ocumented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy ar…
KRAS P.G12C, Non Small Cell Lung Cancer
-
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
avutometinib and sotorasib FDA EUavutometinib and sotorasib and defactinib FDA EU
Known KRAS G12C mutation
Non Small Cell Lung Cancer, KRAS Activating Mutation
-
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
D-1553IN10018
Subject has KRasG12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…
Solid Tumor
-
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Sotorasib FDA EU
Patients who have documentation of KRAS p.G12C prior to enrollment.
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
-
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
BET Bromodomain Inhibitor ZEN-3694Talazoparib
Patients with KRAS G12C mutations must have already had KRAS G12C targeted therapy (e.g., sotorasib) previously
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
-
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
D1553IN10018（Ifebemtinib）
Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…
Solid Tumor
-
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
JDQ443
Presence of a KRAS G12C mutation (all participants) and:
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
AMG 510CisplatinCarboplatinPemetrexed
Identification of a KRAS p.G12C mutation in tumor tissue or plasma by an approved diagnostic device for detection of KRAS…
Lung Cancer
-
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Adagrasib oral dose of 400 mg twice daily tablets FDA EUPembrolizumabChemotherapy: PemetrexedCisplatin/Carboplatin
… unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%.
Advanced NSCLC, Metastatic Lung Cancer
-
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
JAB-21822JAB-21822JAB-21822
Advanced (metastatic or unresectable) KRAS p.G12C mutant solid tumors, with failure or absence of standard treatment
NSCLC, Solid Tumor
-
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Sotorasib FDA EU
Biomarker eligibility for S1900E is based on the identification of a KRAS\^G12C mutation
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
LY3537982PembrolizumabCetuximabPemetrexedCisplatinCarboplatin
Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
-
Study to Evaluate D-1553 in Subjects With Solid Tumors
D-1553D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Subject has KRasG12C mutation in tumor tissue or other bio-specimens containing cancer cells or DNA.
Solid Tumor, Adult, NSCLC, CRC
-
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
AlectinibEntrectinibVemurafenibCobimetinibPralsetinibAtezolizumab
…on in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test, KRAS G12C mutation
Non-small Cell Lung Cancer
-
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
AbemaciclibPI3K Inhibitor paxalisibEntrectinibAdagrasib FDA EU
Similarly, for patients with KRAS G12C mutations, MRTX849 may be used for newly diagnosed brain metastases.
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation
-
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
MRTX849PembrolizumabCetuximabAfatinib
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
-
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
KQB368
Malignancy with either a KRAS G12C or KRAS G12S mutation
Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
-
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
Adagrasib FDA EUIza-bren
Tumor must harbor a KRAS G12C mutation.
Non-small Cell Lung Cancer
-
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
ELI-002 7PTislelizumabmFOLFIRINOX
Presence of one of seven KRAS mutations: G12D, G12V, G12R, G12C, G12A, G12S, or G13D.
Pancreatic Cancer
-
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
HS-10541
…-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
KRAS G12C Mutation Advanced Solid Tumor
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818PembrolizumabPlatinum chemotherapy (cisplatin or carboplatin)PemetrexedCetuximabmFOLFOX6
…ced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
-
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
BMS-986488Adagrasib FDA EUCetuximabNivolumab
i) Part 1B: solid tumors with KRAS G12C mutation.
Advanced Malignant Tumors
-
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
JMKX001899IN10018Chemotherapy: PemetrexedCarboplatin
Known KRAS G12C mutation, and negative results for other driver genes with approved targeted therapies.
NSCLC (Advanced Non-small Cell Lung Cancer)
-
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) FDA EU
…med treatment-naïve of locally advanced or metastatic pancreatic adenocarcinoma harboring KRAS p.G12C mutation assessed by means of a IVDR compliant test) 5) Measurable disease per RECIST 1.1…
Pancreatic Adenocarcinoma
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
KQB365CetuximabKQB198
…ith KQB198): Histologically confirmed diagnosis of a solid tumor malignancy with either a KRAS G12C or KRAS G12S mutation.
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
-
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
ASP5834panitumumab
…alignancy with a documented Kirsten rat sarcoma viral oncogene homolog (KRAS) G12V, G12D, G12C, G12R, G12A or G13D mutation or KRAS amplification (copy number \>/= 4) determined by loc…
Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
-
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
HS-10370HS-20117AdebrelimabCapecitabineOxaliplatinFolinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
Documentation of the presence of a KRAS G12C mutation
Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
-
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
KRAS-mutated mRNA vaccineTORIPALIMABPemetrexed+carboplatin
KRAS G12C/G12D/G12V/G13D mutation-positive by genomic testing.
Malignant Tumors
-
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
JAB-21822standard second-line chemotherapyBevacizumab
KRAS G12C mutation.
Colorectal Cancer
-
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
CarfilzomibSotorasib FDA EU
The tumor must exhibit evidence of KRASG12C mutation which is determined by either a Clinical Laboratory Improvement Act (CLIA) certi…
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
-
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
LY4066434.CetuximabNab paclitaxelGemcitabineOxaliplatinLeucovorin
Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
-
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
HRS-7058 capsule/ HRS-7058 tablet
…inetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation
Advanced Malignant Tumour
-
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
BAY3498264
Histologically confirmed solid tumor malignancy with documented KRAS\^G12C mutation as assessed by an appropriately accredited laboratory.
Advanced Solid Tumors Harboring KRAS G12C Mutation
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
PF-07934040GemcitabineNab-paclitaxelCetuximabFluorouracilOxaliplatin
NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C.
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
-
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
HS-10370AdebrelimabCisplatinCarboplatinPemetrexed
Documentation of the presence of a KRAS G12C mutation
Status may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer, Advanced Solid Tumors
-
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
BBO-8520PembrolizumabBBO-10203
…umented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation
Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
-
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
JSKN016 injection
EGFR, ALK, ROS1, NTRK, BRAF V600, MET exon 14, RET, KRAS G12C, or HER2;
Status may be outdated, last updated 2024-09-19Advanced Malignant Solid Tumor
-
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
AnvumetostatCarboplatinPaclitaxelPembrolizumabPemetrexedSotorasib FDA EU
Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.
Thoracic Tumors, Non-small Cell Lung Cancer
-
Ladarixin With Sotorasib in Advanced NSCLC
Sotorasib FDA EULadarixin
Patients must have documentation of presence of KRASG12C mutation in tumor tissue.
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
-
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
MK-0472PembrolizumabMK-1084
…histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation
Metastatic Solid Tumors, Advanced Solid Tumors
-
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
KRAS-EphA-2-CAR-DCAbraxaneCyclophosphamideAnti-PD-1 antibodyAnti-CTLA4 Monoclonal Antibody
…logy with documentation of tumor EphA2 positive (≥20%) and KRAS mutation (G12V or G12D or G12C) within 6 months prior to screening.
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
-
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
MRTX849IrinotecanCetuximab
Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with KRASG12C mutation.
Colon Cancer, Colorectal Cancer
-
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
Have one of the KRAS mutations (KRASG12C, KRASG12V, KRASG12D, KRASG12A, KRASG13D or KRASG12R) included in the vaccine at the time …
Non-Small Cell Lung Cancer
-
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HBI-2438
Advanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
-
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
IBI351CetuximabpemetrexedCarboplatinSintilimabcis-platinum
Histologically confirmed diagnosis of nonsquamous NSCLC with KRAS G12C mutation
Advanced Non-Small Cell Lung Cancer
-
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
CalderasibPembrolizumabcarboplatinpemetrexedcetuximaboxaliplatin
…e or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease
Advanced Solid Tumors
-
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
BI 1823911BI 1701963Midazolam
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a v…
Solid Tumors, KRAS Mutation
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
GDC-6036AtezolizumabCetuximabBevacizumabErlotinibGDC-1971
Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
-
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Sotorasib FDA EUTrametinibRMC-4630AfatinibPembrolizumabPanitumumab
Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
-
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
HER3-DXd (FL-DP)HER3-DXd (CTM-1 Lyo-DP)HER3-DXd (CTM-3 Lyo-DP)
Has documentation of KRAS-G12C mutation(s) detected from tumor tissue or liquid biopsy.
Non-Small Cell Lung Cancer (NSCLC)
-
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
eDC-KRAS vaccineTislelizumab
…on-small cell lung cancer, etc.) and harboring at least one of the targeted KRAS mutants （G12C/D/R/V）
Advanced Solid Tumor
-
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, …
Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Metastatic Lung Cancer
-
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
fruquintinib+chemotherapybevacizumab+chemotherapy
RAS mutant type.
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
daraxonrasibdocetaxel
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Broad match: KRAS mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
RMC-6236Gemcitabinenab-paclitaxelIrinotecanLiposomal irinotecan5-fluorouracil
RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, …
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
-
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Cadonilimab (AK104) combined with chemotherapy and bevacizumab
Genetic testing revealed RAS (including KRAS and NRAS) mutations, or primary sites located in the right half of the colon (including cecum, rising Colon a…
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-08-22Colorectal Cancer
-
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Adebrelimab + SHR-8068 + Pemetrexed + CarboplatinCamrelizumab + Pemetrexed + CarboplatinAdebrelimab + Pemetrexed + Carboplatin
Participants must have tumors with STK11 or KEAP1 or KRAS mutations.
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-03-28Non-squamous Non-small Cell Lung Cancer
-
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
SintilimabBevacizumabOxaliplatinCapecitabine
RAS mutation, BRAF V600E wild type, and microsatellite stable
Broad match: KRAS mutation (unspecified)Colorectal Cancer Stage IV
-
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
AbemaciclibErlotinib
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer
-
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
SelumetinibDocetaxelPegylated G-CSF
KRAS mutation positive tumour sample as determined by the designated testing laboratory
Broad match: KRAS mutation (unspecified)Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
-
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
CytarabineOral Cladribine
…AML-M5 by FAB or flow cytometry, and/or patients . 60 years with newly diagnosed AML with RAS mutations.
Broad match: KRAS mutation (unspecified)Acute Myeloid Leukemia (AML)
-
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
SelumetinibTrastuzumab Deruxtecan
Patients must have unresectable or metastatic disease with KRAS mutation per Next Generation Sequencing (NGS) tumor testing and HER2 immunohistochemistry (IHC) po…
Broad match: KRAS mutation (unspecified)Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
-
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Tovorafenib
KRAS/NRAS alteration (Strata B or C)
Broad match: KRAS mutation (unspecified)High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma
-
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Daraxonrasib
PARTS A1 AND A2: Patients with relapsed or refractory RAS mutant extracranial solid tumors
Broad match: KRAS mutation (unspecified)Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm
-
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
GFH276with or without TislelizumabPemetrexedCisplatinCarboplatin
Confirmed RAS mutation or KRAS amplification；tumor cell PD L1 test report available
Broad match: KRAS mutation (unspecified)RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
-
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
FurmonertinibFurmonertinibcarboplatinpemetrexed
…es (ALK fusion, ROS1 fusion, RET rearrangement, BRAF mutation, NTRK fusion, MET mutation, KRAS mutation)
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
-
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
LPM6690176BevacizumabFOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (mCRC)
-
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
luvometinib + anlotinibluvometinib + anlotinib
KRAS mutation positive.
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted
-
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Iparomlimab and TuvonralimabCapecitabineBevacizumabOxaliplatin injection
The genetic test results were KRAS or NRAS mutations, without BRAF V600 mutations, and the immunohistochemical results were pMMR;
Broad match: KRAS mutation (unspecified)Rectal Neoplasms Malignant
-
GST101 in Participants With RAS-Mutant Advanced Solid Tumors
GST101
Histologically or cytologically confirmed RAS-mutated advanced solid tumor, with disease progression or intolerance to standard anti-tumor ther…
Broad match: KRAS mutation (unspecified)RAS-mutant Advanced Solid Tumors
-
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Colorectal cancer: Tunlametinib + cetuximab βPancreatic cancer: Tunlametinib + cetuximab βPancreatic cancer: Tunlametinib +Nimotuzumab
Genetic testing demonstrating RAS mutation;
Broad match: KRAS mutation (unspecified)Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer
-
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
Retlirafusp alfa+XELOX+Bevacizumab Treatment
RAS-mutant;
Broad match: KRAS mutation (unspecified)Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
-
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
HRS-2329 TabletNimotuzumabHS-20093Adebrelimab
RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, RAS Mutations or Amplifications
-
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
GFH276CetuximabNab paclitaxelGemcitabineFluorouracilLeucovorin
…cally or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
-
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
BevacizumabFOLFIRIPelareorep
Tumor confirmed to harbor a known RAS mutation per a standard local testing method
Broad match: KRAS mutation (unspecified)Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
-
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
vopimetostatERAS-0015
…ed, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only…
Broad match: KRAS mutation (unspecified)PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
-
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
NK CellsNK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapyNK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapyNK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapyNK cells + PD-(L)1 inhibitor + capecitabine or S-1 as first-line maintenance therapy
…: EGFR sensitive mutations, ALK gene rearrangements, ROS1 mutations, BRAF 600E mutations, KRAS mutations);
Broad match: KRAS mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
-
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
BPI-572270
Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
-
Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Tunlametinib + Cetuximab βTunlametinib + Fulzerasib
Positive for KRAS driver gene mutations (including: KRAS G12C and KRAS non-G12C).
Broad match: KRAS G12CLung Cancer (NSCLC)
-
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Daraxonrasib
Documented KRAS mutation
Broad match: KRAS mutation (unspecified)Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
-
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
DaraxonrasibElironrasibZoldonrasibIvonescimabCarboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)cetuximab (Cohort C2 Only)
…ogically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
-
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
HRS-7172 + AG + SHR-1316HRS-7172 + AG + SHR-1316;HRS-7172 + AG;HRS-7172 + AG + SHR-1316;HRS-717 + HRS-4642+SHR-1316;HRS-717 + HRS-4642+SHR-1316;
…ocally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing.
Broad match: KRAS mutation (unspecified)Pancreatic Cancer
-
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Spedox-6PegfilgrastimFilgrastim
…lative to normal tissue including: STS, TNBC, cervical cancer, NSCLC, ovarian cancer, and KRAS mutated pancreatic ductal adenocarcinoma without requirement for testing FcRn level.
Broad match: KRAS mutation (unspecified)Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
isunakinra
Tumor is determined to be RAS-mutated (KRAS, NRAS or HRAS) and microsatellite stable/proficient in mismatch repair, as assessed…
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic
-
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
standard second line treatment, at discretion of the investigatorRegorafenib (BAY73-4506)
RAS mutant at initial diagnosis assessed at local centers according with a validated method defined …
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic
-
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373BalstilimabCyclophosphamideGVAXAGEN2373 (RP2D)Balstilimab
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resec…
Broad match: KRAS mutation (unspecified)Pancreatic Cancer
-
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
SerplulimabChemotherapyTargeted therapy
…mary tumor located in the cecum, ascending colon, and proximal transverse colon, and RAS (KRAS and NRAS) mutant-type (Cohorts C and D);
Broad match: KRAS mutation (unspecified)Advanced Colorectal Carcinoma, Immunotherapy
-
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
Collect tumor tissue for PD-L1, CD8 expression level determination, and MSI, TMB, KRAS, BRAF, PIK3CA, NRAS, PTEN, EGFR, HER2, HRAS, KIT, MET, ROS1, POLE, POLD1, TP53 gene mutation detection
Broad match: KRAS mutation (unspecified)Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462RMC-9805RMC-6236mFOLFIRINOXgemcitabine/nab-paclitaxel
Arms A and B only: Has a tumor with a RAS mutation
Broad match: KRAS mutation (unspecified)PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523GemcitabineNab-PaclitaxelCetuximabPembrolizumab
…etastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).
Broad match: KRAS mutation (unspecified)Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
-
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
WEF-001
Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung can…
Broad match: KRAS mutation (unspecified)Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
-
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Iparomlimab/TuvonralimabBevacizumab + CAPEOX
Genetic testing results confirming either RAS mutation or right-sided colon location with RAS wild-type status, absence of BRAF V600E mutation, …
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
-
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
GFH276
… Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
Broad match: KRAS mutation (unspecified)Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
-
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
JYP0015
Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
Broad match: KRAS mutation (unspecified)Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
-
A Clinical Study of Arfolitixorin in Patients With mCRC
Arfolitixorin
Phase 1b: Histologically confirmed RAS mutant, MSS/pMMR, colorectal adenocarcinoma with metastatic disease, eligible for first-line the…
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (mCRC)
-
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
PD-1 InhibitorsCapeOX + bevacizumab
RAS mutation-positive.
Broad match: KRAS mutation (unspecified)Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer
-
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIDrug: XS-03Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
Documentation of RAS mutation.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
-
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Test product: HYP-2090PTSA
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Broad match: KRAS mutation (unspecified)Safety, Tolerability, Efficacy
-
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Azacitidine (AZA) Days 1 - 5Decitabine (DAC)Venetoclax
High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.
Broad match: KRAS mutation (unspecified)T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse
-
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
SerplulimabCapecitabineOxaliplatin
MSS/RAS mutation patients with clinical stages T3N1-2 and T4N0-2
Broad match: KRAS mutation (unspecified)Colon Cancer
-
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
TislelizumabCisplatinCarboplatinPemetrexed Disodium
With Known KRAS gene mutation.
Broad match: KRAS mutation (unspecified)Lung Cancer, Non-Small Cell
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
DurvalumabTremelimumabPemetrexedPembrolizumabCarboplatinCisplatin
Participants must have tumors with STK11 or KEAP1 or KRAS mutations.
Broad match: KRAS mutation (unspecified)Carcinoma, Non-Small-Cell Lung
-
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Intrathecal pemetrexed
…fusion, and other oncogenic alterations including RET fusion, BRAF mutation, NTRK fusion, KRAS mutation was confirmed by an accredited local laboratory.
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer
-
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Cadonilimab + bevacizumab + FOLFOX
RAS mutation;
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-01-23Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
-
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
SunvozertinibCrizotinibPralsetinibLarotrectinibSavolitinibPyrotinib
…s of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.
Broad match: KRAS G12CLung Cancer Stage III, Mutation
-
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
AvutometinibDefactinibNivolumab
COHORT A ONLY: Patients must have known KRAS mutation
Broad match: KRAS mutation (unspecified)Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RMC-6236mFOLFOX6 regimenbevacizumabmFOLFIRINOX regimencetuximabgemcitabine
…reatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unre…
Broad match: KRAS mutation (unspecified)Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
-
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
TrametinibAnlotinibTislelizumab
KRAS mutation positive detected by ARMS or NGS;
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-13KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
-
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
OnvansertibFOLFIRIBevacizumabFOLFOX
Documented KRAS or NRAS mutation.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
-
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
JAB-23E73JAB-23E73
…f a locally advanced, unresectable, and/or metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification).
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
AvutometinibDefactinib
…ecurrent tumor, or metastases) possess at least one of the following genetic alterations: RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, Class 2 or 3 BRA…
Broad match: KRAS mutation (unspecified)Thyroid Cancer
-
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
TG01
RAS mutation (KRAS/NRAS codon 12/13 mutation) detected on archival or fresh bone marrow material with …
Broad match: KRAS mutation (unspecified)Multiple Myeloma, Smoldering Multiple Myeloma
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
GNS561 + Trametinib
Histologically confirmed intrahepatic CCA with a documented KRAS mutation.
Broad match: KRAS mutation (unspecified)Cholangiocarcinoma
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Avutometinib (VS-6766) + defactinib
Tumor with known RAS mutation, BRAF (type I, II, and/or III) mutation, NF-1 and/or RAS activation status determined fro…
Broad match: KRAS mutation (unspecified)Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer
-
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
Cetuximab
Metastatic colorectal cancer with tissue RAS mutation-type;
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-04Colorectal Cancer Metastatic
-
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
DexamethasoneAnisodamineOxaliplatinLeucovorinFluorouracilIrinotecan
…us Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical S…
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RMC-6236
…ally confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
-
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
TG01 VaccineQS-21Balstilimab
Screening tumor tissue positive or known pathogenic or likely pathogenic RAS mutation resulting in amino acid substitution in codon 12A, 12C, 12D, 12R, 12S or 13D .
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-09-23Pancreas Cancer
-
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
IMM-1-104 Monotherapy (Treatment Group A)IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)IMM-1-104 + modified FOLFIRINOX (Treatment Group C)IMM-1-104 + dabrafenib (Treatment Group D)IMM-1-104 + pembrolizumab (Treatment Group E)
…sectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
-
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Cobimetinib
…atopoietic cell sequencing results on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%.
Broad match: KRAS mutation (unspecified)Chronic Myelomonocytic Leukemia (CMML)
-
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
CyclophosphamideFludarabineMutant KRAS G12V-specific TCR transduced autologous T cellsAnti-PD-1 monoclonal antibody
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009venetoclaxazacitidine
KRASmut: 1 point
Broad match: KRAS mutation (unspecified)Hematologic Malignancies
-
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
TVB-2640
…histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.
Broad match: KRAS mutation (unspecified)KRAS Gene Mutation
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
CyclophosphamideFludarabineAnti-KRAS G12V mTCR PBLAldesleukin
…surable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing…
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer
-
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
DocetaxelTrametinib
DISEASE RELATED CRITERIA: Patients must have pathologically confirmed KRAS mutation (at codon 12, 13 and 61) positive non-small cell lung cancer (NSCLC) that is stage IV or …
Broad match: KRAS mutation (unspecified)KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
-
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
NavitoclaxTrametinib
Patients must have histologically- or cytologically-confirmed diagnosis of KRAS or NRAS mutation-positive malignancy that is metastatic or unresectable and for which standard curative me…
Broad match: KRAS mutation (unspecified)Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
-
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Cabozantinib S-malateErlotinib Hydrochloride
…t least one alternative driver mutation, i.e: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation, human epidermal growth fa…
Broad match: KRAS mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
-
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
AN9025 oral capsule
Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …
Broad match: KRAS mutation (unspecified)Solid Tumors (Phase 1), RAS Mutation
-
TCR1188-ABC Cells in KRAS-mutated Cancers
TCR1188-ABC cellsFludarabine + Cyclophosphamide combinationTocilizumab
TCR1188-ABC Cells in KRAS-mutated Cancers
Broad match: KRAS mutation (unspecified)Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
-
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
AvutometinibdefactinibEverolimus
Participants must have histologically or cytologically confirmed recurrent RAS mutant endometrial cancer.
Broad match: KRAS mutation (unspecified)Phase IB, Avutometinib, RAS Pathway, Endometrial
-
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
ONVAX-01 plus Anti-PD-1 and Chemotherapy
Histologically confirmed, KRAS-mutated, unresectable metastatic pancreatic ductal adenocarcinoma (PDAC).
Broad match: KRAS mutation (unspecified)Advanced Pancreatic Adenocarcinoma
-
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051Gemcitabine/nab-paclitaxelCetuximabPembrolizumabmFOLFOX6FOLFIRI
Documentation of KRAS mutation prior to the first dose of trial drug(s).
Broad match: KRAS mutation (unspecified)KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
-
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
aldesleukincyclophosphamidefludarabine phosphateIndividual Patient TCR-Transduced PBL
Detection of at least one of the neoepitope-forming TP53 or RAS mutations that are listed in Table 3 in on the TruSight Oncology (TSO) 500 sequencing panel (NSR d…
Broad match: KRAS mutation (unspecified)Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
-
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
ASKC189
Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …
Broad match: KRAS mutation (unspecified)Solid Tumor, RAS Mutation
-
Study of ABO2102 in KRAS-Mutated Solid Tumors
ABO2102 InjectionSintilimab injection
…e genetic testing during the screening period, with evidence of harboring any of required KRAS mutations
Broad match: KRAS mutation (unspecified)Advanced / Metastatic Solid Tumor
-
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
Intravenous AN4035Intravenous AN4035 followed by intravenous EGFR Inhibitor.
Documentation of KRAS/NRAS/HRAS mutation determined by a Sponsor-approved validated local testing of tumor tissue or cfDNA in a CL…
Broad match: KRAS mutation (unspecified)Solid Tumor (Phase I), RAS Mutation, CEACAM5
-
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
ABSK211
…pants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration
Broad match: KRAS mutation (unspecified)Solid Tumor (Phase I)
-
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410PembrolizumabPanitumumab
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Broad match: KRAS mutation (unspecified)KRAS Altered Advanced or Metastatic Solid Tumors
-
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
MK-4716PembrolizumabCetuximab
…716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration
Broad match: KRAS mutation (unspecified)Malignant Neoplasm
-
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
HRS-7172 Tablets
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Harboring RAS Mutations or Amplifications
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ALTA3263cetuximabmFOLFOX6PembrolizumabPemetrexed + Cisplatin /CarboplatinmFOLFIRINOX
Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Impro…
Broad match: KRAS mutation (unspecified)Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RO7673396
Confirmed presence of the RAS mutation(s)
Broad match: KRAS mutation (unspecified)Neoplasms
-
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BGB-58067BG-89894RAS(ON) Inhibitors
documented RAS mutation status or KRAS mutation is required for selected cohorts
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
RX001
Subjects with valid biopsy results documented the presence of KRAS mutation.
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer
-
Study of AUBE00 in Patients With Solid Tumors
AUBE00Cetuximab
Patients with Kirsten rat sarcoma (KRAS) alteration confirmed by local tests or central laboratory test (Details are defined for each part)
Broad match: KRAS mutation (unspecified)Solid Tumors
-
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
HRS-2329 Tablet
…mors who have been previously tested or are confirmed by the central laboratory to harbor RAS mutations or amplifications and have failed standard treatment;
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Harboring RAS Mutations or Amplifications
-
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
M3T01PembrolizumabFOLFOX regimen
…oved therapy is available (including but not limited to EGFR, ROS1, ALK, BRAF, RET, NTRK, KRAS G12C, etc.) should have received this therapy.
Broad match: KRAS G12CAdvanced Solid Tumors
-
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
BalstilimabBotensilimab
…cally confirmed microsatellite stable (MSS) metastatic colorectal adenocarcinoma with any KRAS mutation (as determined by a Clinical Laboratory Improvement Act \[CLIA\]-certified lab), includin…
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
-
TLN-372 in Advanced KRAS Mutant Solid Tumors
TLN-372TLN-372 in combination with cetuximabTLN-372 in combination with pembrolizumab
Patients must have locally advanced or metastatic KRAS mutant solid tumors.
Broad match: KRAS mutation (unspecified)KRAS Mutant Solid Tumors
-
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
KRAS-specific Autologous TCR-T cell injection
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Broad match: KRAS mutation (unspecified)Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
BBO-10203TrastuzumabFulvestrantRibociclibFOLFOXBevacizumab
…-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aN…
Broad match: KRAS mutation (unspecified)Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
-
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
AnvumetostatGemcitabineNab-paclitaxelModified FOLFIRINOXRMC-6236
Rat Sarcoma Viral Oncogene Homolog (RAS) mutation
Broad match: KRAS mutation (unspecified)Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
AldesleukinFludarabineCyclophosphamideKRAS TCR-Transduced PBLGRT-C903/GRT-R904
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metast…
Broad match: KRAS mutation (unspecified)Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
-
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
MPD-1
KRAS mutation or PTEN loss is confirmed in tumor tissues prior to screening, and there is a documented …
Broad match: KRAS mutation (unspecified)Cancer, Solid Tumor Cancer, Biomarkers
-
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
KRAS Vaccine with Poly-ICLC adjuvantBalstilimabBotensilimab
Have one of the KRAS mutations included in the vaccine at the time of vaccination expressed in tumor.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Cancer
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12DAZD0240: Autologous, engineered T Cells targeting KRAS G12D
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
-
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
SYS6023
…sion, RET rearrangement, HER2 mutation, Met exon 14 skipping mutation, Met amplification, KRAS G12c mutation, etc.), locally advanced or metastatic non-small cell lung cancer, previously tr…
Broad match: KRAS G12CAdvanced Solid Tumor
-
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NEROFEDoxorubicin
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Broad match: KRAS mutation (unspecified)Solid Tumor, KRAS Mutation-Related Tumors
-
A Study of Avutometinib for People With Solid Tumor Cancers
Avutometinib
…ase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations, KRAS/NRAS/HRAS alterations, PTPN11 or SOS1/2 mutations and/or loss of function alterations in NF1.
Broad match: KRAS mutation (unspecified)Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
DarlifarnibCabozantinibAdagrasib FDA EU
…eceived at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC.
Broad match: KRAS G12CSolid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
-
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
TY-2699a
…n cancer, small cell lung cancer, castrate-resistant prostate cancer (CRPC), or PDAC with KRAS mutant
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-11-07Solid Tumor, Adult
-
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
BET Bromodomain Inhibitor ZEN-3694Binimetinib
Solid tumor with genomic alteration(s) activating RAS signaling including activating KRAS, NRAS, HRAS, or BRAF mutations, inactivating NF1 mutations, or BRAF fusions
Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma
-
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Cohort A: Patients at high risk of developing pancreatic cancer.Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
… Patients must have cystic fluid testing that demonstrates the presence of one of the six KRAS mutations included in the study vaccine.
Broad match: KRAS mutation (unspecified)High Risk Cancer, Pancreatic Cancer
-
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HBI-2376
Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
-
AB122 Platform Study
AB122AB122TAS-116TAS-120TAS-115TAS-102
…ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type. \[Mutant is defined as at least KRAS or NRAS mutant (any exon, any mutation)\].
Broad match: KRAS mutation (unspecified)Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-1255 Dose EscalationRSC-1255 Dose Expansion
Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS
Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
-
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
KRAS peptide vaccineNivolumabIpilimumab
…ecurrence or distant metastasis noted on imaging \> 12 months after the first dose of the mutant KRAS peptide vaccine with poly-ICLC adjuvant.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Cancer
-
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
BinimetinibPembrolizumab
Provide archival tumor tissue sample for KRAS/BRAF/STK11 mutation analysis or newly obtained core or excisional biopsy of a tumor lesion not previously irr…
Broad match: KRAS mutation (unspecified)Non-small Cell Carcinoma
-
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
BI 1701963Trametinib
Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening
Broad match: KRAS mutation (unspecified)Solid Tumors, KRAS Mutation; SOS1
-
Phase I Trial of Defactinib and VS-6766.
VS-6766Defactinib
… no conventional therapy exists or is declined by the patient enriching for patients with RAS mutant solid tumours.
Broad match: KRAS mutation (unspecified)NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
-
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
TCR-T cellsFludarabineCyclophosphamide
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Broad match: KRAS mutation (unspecified)KRAS G12V, KRAS G12D, Solid Tumor
-
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
ABO2102Toripalimab
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
Broad match: KRAS mutation (unspecified)Pancreatic Neoplasms, Other Solid Tumors
-
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Fixed neoantigen tumor vaccinepersonalized neoantigen tumor vaccinePD-1 inhibitor
… neoantigen effectively presented by the patient's HLA type, including those derived from KRAS or TP53 mutations.
Broad match: KRAS mutation (unspecified)Pancreatic Cancer Resectable, Chemotherapy-intolerant
-
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Personalized neoantigen tumor vaccine
…tics analysis, at least one antigen effectively presented by self-HLA was found , such as KRAS or TP53 mutations and correspondingly presented HLA types
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-10-26Advanced Pancreatic Cancer
-
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
Personalized neoantigen tumor vaccinePD-1 inhibitor
…tics analysis, at least one antigen effectively presented by self-HLA was found , such as KRAS or TP53 mutations and correspondingly presented HLA types
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
Tunlametinib combined with Fruquintinib
4)Previous gene testing results indicate positive RAS mutation
Broad match: KRAS mutation (unspecified)CRC, Colorectal Cancer
-
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
individualized mRNA neoantigen vaccine (mRNA-0523-L001)
…they predict at least one antigen that is effectively presented by their own HLA, such as KRAS or TP53 mutations and corresponding HLA typing, see 1.4 for the rationale of the topic.
Broad match: KRAS mutation (unspecified)Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
-
MRD Monitoring in Colorectal Cancer Using ctDNA
Presence of KRAS gene mutation (specifically G12 or G13 mutations) confirmed in the primary tumor tissue.
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease
-
Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness
KRAS/NRAS/BRAF mutation or right-sidedness;
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-05-31Colorectal Carcinoma, Liver Metastases
-
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Colorectal cancer with RAS mutation (KRAS or NRAS)
Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-13Colorectal Liver Metastasis
-
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Sotorasib FDA EUPanitumumabTrifluridine and TipiracilRegorafenib
Pathologically documented metastatic colorectal adenocarcinoma with Kirsten rat sarcoma (KRAS) p.G12C mutation as determined by prospective central testing, using the analytically validated Q…
Colorectal Cancer (CRC)
-
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
AMG 510Docetaxel
…ocumented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation …
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
-
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
OlomorasibPembrolizumab
Known KRAS G12C mutation identified on tumor tissue or circulating tumor DNA (ctDNA) as determined by mol…
Lung Cancer, Lung Cancer (NSCLC), Locally Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
-
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
Sotorasib FDA EULenvatinib
KRASG12C-mutation (identified through local molecular testing, using a validated test).
Metastatic Non Small Cell Lung Cancer, KRAS G12C
-
JDQ443 for KRAS G12C NSCLC Brain Metastases
JDQ443
Metastatic (stage IV) NSCLC with the presence of a KRAS G12C mutation (local test, tissue as well as liquid biopsy allowed) and untreated or progressi…
Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C
-
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Sotorasib FDA EULadarixin
Patients must have documentation of presence of KRASG12C mutation in tumor tissue.
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
-
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
IMM-6-415
KRASG12C mutant participants must have received prior treatment with a KRASG12C inhibitor for any …
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
-
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
DurvalumabSotorasib FDA EU
KRAS p.G12C mutation identified through molecular testing
Non-Small Cell Lung Cancer
-
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Milciclib Dose: 150 mg/day Mode of administration: oral
…12F, G12R, G12S, G12V, or G13D KRAS mutation, or, any pathogenic KRAS mutation other than G12C, as determined by a Sponsor-approved laboratory
NSCLC
-
CISH Inactivated TILs in the Treatment of NSCLC
FludarabineCyclophosphamideCISH Inactivated TILAldesleukinPembrolizumab
…ymphoma kinase \[ALK\], reactive oxygen species \[ROS\], Kirsten RAt Sarcoma Virus G12C \[KRAS G12C\], human epidermal growth factor receptor 2 \[HER2\], neurotrophic tyrosine receptor kina…
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
-
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
BMS-986466Adagrasib FDA EUCetuximab
Individuals with a confirmed diagnosis of advanced KRAS G12C mutant NSCLC, CRC, PDAC and BTC that has spread to other parts of the body and cannot be …
Advanced Solid Tumors
-
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
Adagrasib FDA EUAdagrasib/Nivolumab FDA EU
Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C mutation.
Resectable Non-Small Cell Lung Cancer
-
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Oral sotorasib + IV Panitumumab FDA EU
…metastatic solid tumors (excluding non-small cell lung cancer and colorectal cancer) with KRAS G12C mutation detected through local next-generation sequencing analysis.
Efficacy
-
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
GFH925Cetuximab
Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC.
Advance Non-small Cell Lung Cancer
-
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Sotorasib FDA EULiposomal Irinotecan (nal-IRI)5 Fluorouracil (5FU)Leucovorin (LV)Gemcitabine (GEM)Nab paclitaxel
G12C mutation by CLIA certified molecular testing of tumor biopsy or blood based circulating t…
Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
-
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
AMG 510MVASI
Histologically proven, locally advanced, recurrent or metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC), with pathological documentation of KRAS p.G12C…
Non Small Cell Lung Cancer
-
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) FDA EU
Patients must have non-squamous NSCLC with KRAS G12C mutation identified through molecular testing (local assessment), AJCC 8 stages Ib, IIa, …
Non-Small Cell Lung Cancer
-
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
sotorasib FDA EU
Documented KRASG12C mutation, based on tissue analysis on either archived tissue or new biopsy before inclusi…
Lung Cancer, NSCLC, Stage III, NSCLC Stage IV, Lung Cancer Stage IV
-
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Sotorasib and Tarloxotinib FDA EUSotorasib and Tarloxotinib FDA EU
Histologically confirmed diagnosis of squamous or non-squamous NSCLC with KRAS G12C mutation
Non-Small Cell Lung Cancer
-
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
avutometinib (VS-6766) and adagrasib FDA EU
Known KRAS G12C mutation
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer
-
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
D-1553Other
Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA.
NSCLC
-
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Sotorasib FDA EU
Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)
Non-small Cell Lung Cancer
-
An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib
sotorasib FDA EU
4. have documentation of KRAS p.G12C mutation confirmed by local testing through the current protocol or have documentation of…
Non Small Cell Lung Cancer
-
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
…l Growth Factor Receptor), ALK (Anaplastic Lymphoma Kinase), ROS1 (ROS Proto-Oncogene 1), KRAS G12C (Kirsten Rat Sarcoma Viral Oncogene), BRAF V600E (v-raf murine sarcoma viral oncogene hom…
Non-Small Cell Lung Cancer
-
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
JAB-21822 (KRAS G12C inhibitor)JAB-21822 (KRAS G12C inhibitor)JAB-21822 (KRAS G12C inhibitor)Cetuximab (EGFR inhibitor)
Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
Advanced Solid Tumor, NSCLC, CRC
-
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
GFH925
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
KRAS G12C
-
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
YL-15293
Part 1 only - metastatic or locally advanced solid tumor malignancies positive for KRAS G12C that has progressed on, is refractory to, intolerant to, or for which there is no curativ…
Advanced Solid Tumor
-
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
RMC-4630Sotorasib FDA EU
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Non-Small Cell Lung Cancer
-
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
VociprotafibPembrolizumabAdagrasib FDA EU
Participants must have following molecular aberration (Part 3A and 3B): - KRAS G12C mutation.
Metastatic Neoplasm
-
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
eFT226Sotorasib FDA EUFulvestrantAbemaciclibTrastuzumab
Tumor has a known G12C KRAS-activating mutation.
Solid Tumor, Adult
-
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
LY3499446AbemaciclibCetuximabErlotinibDocetaxel
Participants must have diagnosis of a solid tumor with KRAS G12C mutation that did not respond to at least 1 line of standard therapy and has spread to ot…
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
-
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
sotorasib FDA EUAnti PD-1/L1Midazolam
Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.
KRAS p.G12C Mutant Advanced Solid Tumors
-
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
LY3537982
Have disease with evidence of KRAS G12C mutation
Advanced Solid Tumors
-
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Adagrasib FDA EUOlaparib
… escalation cohort: Histologically confirmed diagnosis of a solid tumor malignancy with a KRAS G12C mutation.
Advanced Solid Tumor, Non-small Cell Lung Cancers
-
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Adagrasib FDA EUnab-Sirolimus
…logically confirmed diagnosis of solid tumor malignancy (Phase 1) or NSCLC (Phase 2) with KRAS G12C mutation
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer
-
Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
BEBT-607Tablets
For patients with KRAS G12C mutation, previously confirmed genomic KRAS GI2C mutation results in tumor tissue specime…
Advanced or Metastatic Solid Tumor, KRAS G12C Mutation
-
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
DurvalumabAdagrasib FDA EU
Presence of KRAS G12C mutation detected by assay performed in a CLIA-certified environment.
Lung Cancer, Gastro-intestinal Cancer
-
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
SY-5933
…s must have histologically or cytologically confirmed advanced solid tumors harboring the KRAS p.G12C mutation and have progressed after standard therapy, or standard therapy is inappropriate…
Advanced Solid Tumor
-
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
MRTX849 FDA EU
Histologically confirmed diagnosis of a pancreatic cancer with KRAS G12C mutation.
Metastatic Pancreatic Cancer
-
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
Temporary Stopping
KRASG12C mutation
Non-small Cell Lung Cancer Metastatic
-
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
INCB099280adagrasib FDA EU
KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue…
Advanced Solid Tumors
-
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
BBP-398sotorasib FDA EU
…ted, locally advanced and unresectable, or metastatic solid tumor with documentation of a KRAS-G12C mutation within 2 years prior to screening.
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
-
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
MRTX0902MRTX849 FDA EU
MRTX0902 and adagrasib combination therapy: KRAS G12C mutation.
Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
-
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
IBI351Cetuximab
2. have documentation of KRAS G12C mutation
Colorectal Cancer
-
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
MRTX849 FDA EUPalbociclib
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Advanced Solid Tumor
-
A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors
RNA tumor vaccineRNA tumor vaccine+Navuliumab
Identification of at least one KRAS mutation: G12C, G12D or G12V;
Advanced Solid Tumor
-
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
MRTX849
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation.
Advanced or Metastatic Solid Tumor
-
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
VIC-1911sotorasib FDA EU
Have locally advanced or metastatic histologically or cytologically confirmed NSCLC, KRAS G12C-mutated
Non-small Cell Lung Cancer
-
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
InlexisertibTrametinibBinimetinibSotorasib FDA EU
Participants enrolled in the inlexisertib and sotorasib cohort (Cohort D) must have a KRAS G12C mutation.
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
-
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
ERAS-007ERAS-601OsimertinibSotorasib FDA EU
…cally confirmed NSCLC, with presence of EGFR mutation(s) sensitive to EGFR inhibitors, or KRAS G12C mutation.
Advanced Non-squamous Non-small-cell Lung Cancer
-
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
NB004 tablets FDA EU
Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority …
Advanced Solid Tumor
-
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
GEC255 tablets
Has histologically or cytologically confirmed advance tumors with KRAS p.G12C mutation and has poor response to standard of care therapy or intolerant to standard of c…
Advanced Solid Tumors
-
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
MRTX849 FDA EUBI 1701963
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung
-
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
GH35 Tablet
…acodynamics and Preliminary Antitumor Activity of GH35 Tablets in Patients Harboring With G12C Mutation in Advanced Solid Tumors
Advanced Solid Tumors Harboring With G12C Mutation
-
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
TrametinibAnlotinib
KRAS mutation positive excluded KRASG12C mutation.
Non Small Cell Lung Cancer
-
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
AMG 510
Pathologically documented, advanced/metastatic solid tumor with KRAS p.G12C mutation identified
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
-
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
MRTX849 FDA EUTNO155
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
-
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
JNJ-74699157
Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumor tissue or blood
Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
-
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
RMC-4630
…sion Component must have one of the following genotypic aberrations: KRAS amplifications, KRASG12C (NSCLC), BRAF Class 3, or NF1 LOF (NSCLC and gynecological cancers) mutations
Solid Tumors
-
DC Vaccine in Pancreatic Cancer
mDC3/8-KRAS Vaccine
Pathologically-confirmed KRAS(G12D-), KRAS(G12V-), KRAS(G12R-) or KRAS(G12C-mutated) pancreatic ductal adenocarcinoma who are at high risk of relapse and have no evi…
Pancreatic Ductal Adenocarcinoma
-
GI-4000 With Adoptive Transfer in Pancreatic Cancer
GI-4000 VaccineGI-4000 Vaccine + Activated T CellsSurgical Evaluation after Vaccine #4
…reatic adenocarcinoma that expresses one of the GI-4000-related k-ras oncoproteins (G12V, G12C, G12D, Q61L, or Q61R)
Pancreatic Cancer
-
Therascreen® KRAS RGQ PCR Kit
…amples from Patients with Colorectal Cancer (CRC) Who Have Previously Tested Positive for KRAS G12C Mutation Into the Amgen Phase III Clinical Trial (Protocol No 20190172) to Demonstrate Cl…
Colo-rectal Cancer
-
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
avastinmFOLFOX6
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms
-
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
mFOLFOXIRI regimenmFOLFOX regimenBevacizumab
RAS mutation and BRAF V600E wild-type;
Broad match: KRAS mutation (unspecified)Colorectal Carcinoma, Liver Metastases
-
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
IrinotecanOxaliplatin HAIFloxuridineLeucovorin5-FUOxaliplatin
Unsuitable for cetuximab treatment(RAS mutation, unable to afford the cost).
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer, Liver Metastases
-
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Panitumumab
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Broad match: KRAS mutation (unspecified)Colon Cancer Stage III
-
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
carboplatinpaclitaxelBevacizumabPemetrexedcisplatin
Documented KRAS mutation
Broad match: KRAS mutation (unspecified)Carcinoma, Non-Small Cell Lung
-
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
mFOLFOX6HAI
Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it)
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Modified FOLFOX6Aflibercept
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
-
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
cetuximabbrivanib alaninate
…tumor tissue by a central reference laboratory (archival tumor samples are acceptable for K-Ras mutation analysis)
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
MirdametinibSirolimus
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Broad match: KRAS mutation (unspecified)Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
-
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
CetuximabPanitumumab5-FluorouracilBevacizumabCapecitabine
RAS mutated and/or right-sided primary tumor
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic
-
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
T3011 + Cobimetinib
BRAF V600E/V600K mutation-positive (applied to part 1 and part 2 cohort 1) or RAS mutation-positive (applied to part 1 and part 2 cohort 2).
Broad match: KRAS mutation (unspecified)Melanoma, Malignant Melanoma
-
RP-6306 in Patients With Advanced Cancer
RP-6306GemcitabineFOLFIRI ProtocolTrastuzumabRP-3500
Patients must have both a RAS mutation (KRAS) and a TP53 mutation based on local testing\*.
Broad match: KRAS mutation (unspecified)Advanced Cancer
-
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Mirdametinib 2mgBGB-3245 5mgMirdametinib 3mgMirdametinib 4mgBGB-3245 10mgBGB-3245 20mg
Cohort B: non-small cell lung cancer (NSCLC) harboring a KRAS mutation.
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
Histologically confirmed initially unresectable MSS/pMMR-type RAS-mutant metastatic colorectal adenocarcinoma;
Broad match: KRAS mutation (unspecified)Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine
-
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
LeflunomideThe combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
Must have documented RAS (KRAS, HRAS, NRAS) mutation identified within the last 5 years by a local test on tumor tissue.
Broad match: KRAS mutation (unspecified)RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer
-
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
OmpenaclidBevacizumabFOLFIRI regimen
…r of adenocarcinoma or poorly differentiated histology that is laboratory-confirmed to be RAS mutant.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Metastatic Colon Cancer
-
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
OnvansertibFOLFIRIBevacizumab
… Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Metastatic Colorectal Cancer
-
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
PD-1BevacizumabOxaliplatinCalcium folinate5-fluorouracil
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Broad match: KRAS mutation (unspecified)Rectal Cancer
-
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
intensive treatmentMaintenance treatment
RAS mutation;
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
VS-6766/avutometinibCetuximab
…ave metastatic colorectal adenocarcinoma with kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, detected by any Clinical Laboratory Improvement Amendments-certified method (tumor or ct…
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma
-
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Nanrilkefusp alfaCetuximab
locally performed ctDNA assessment including at least mutations in exon 2 (G12D, G12V, G12C, G12S, G12A, G12R, G13D) and determined by a laboratory using validated test methods
Broad match: KRAS G12CColorectal Cancer
-
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
TrametinibHydroxychloroquine
The tumor must have Kirsten rat sarcoma (KRAS) mutation(s) of clinical significance, confirmed by National Cancer Institute (NCI) Laboratory of P…
Broad match: KRAS mutation (unspecified)Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
-
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
FruquintinibFOLFIRImFOLFOX6
RAS mutation
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Combination: Fruquintinib + FOLFIRI
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Bevacizumab+mFOLFOX6
An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High;
Broad match: KRAS mutation (unspecified)Neoadjuvant Treatment, Rectal Cancer, Bevacizumab, Radiotherapy
-
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
YL-15293
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer
Intra-arterial LIOX + Capecitabine
Genotype: RAS mutant for first line patients only.
Broad match: KRAS mutation (unspecified)Liver Metastasis Colon Cancer
-
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
VemurafenibSorafenib
Histologically confirmed cancer of the pancreas (KRAS mutated) with metastases and progression on at least ≥ 2 prior treatment regimens for their disea…
Broad match: KRAS mutation (unspecified)Pancreas Cancer
-
Study to Evaluate D-1553 in Subjects With Lung Cancer
D-1553
Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA.
Broad match: KRAS G12CNSCLC
-
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
KRAS/NRAS mutation;
Broad match: KRAS mutation (unspecified)Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
-
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
DurvalumabCarboplatinPemetrexed
Histological or cytological evidence of stage IV Kras mutation positive non-squamous NSCLC.
Broad match: KRAS mutation (unspecified)Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
-
Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Fruquintinib
Histologically and/or cytologically confirmed metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer, having unresectable metastatic or recurrent foci;
Broad match: KRAS mutation (unspecified)Colo-rectal Cancer
-
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Binimetinib PillHydroxychloroquine Pill
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
-
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
ERAS-007EncorafenibCetuximabPalbociclib
KRAS or NRAS mutations) or metastatic PDAC harboring KRAS mutation based on an analytically validated assay performed on tumor tissue in a certified testing…
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
-
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
SelinexorPembrolizumabTrifluridineTipiracil
…y proven diagnosis of unresectable metastatic colorectal cancer with a known rat sarcoma (RAS) mutation.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
TPX-0005Trametinib
…cytological confirmation of unresectable or metastatic solid tumor malignancy harboring a KRAS mutation.
Broad match: KRAS mutation (unspecified)KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
-
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
investigator choice re-challenge with anti EGFR Rx
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Broad match: KRAS mutation (unspecified)Colon Cancer
-
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
OMO-103
Histologically or cytologically proven advanced NSCLC whose tumours are KRAS-mutated and where the disease has progressed after a chemotherapy and immunotherapy regimen (at l…
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors, Pancreatic Cancer, CRC
-
The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients
Ascorbic Acid
with KRAS and BRAF mutation
Broad match: KRAS mutation (unspecified)Colon Cancer Stage Iv
-
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
SerabelisibCanagliflozin 300mg
…b in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations
Broad match: KRAS mutation (unspecified)Breast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer
-
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
CetuximabIrinotecan
Unresectable metastatic RAS mutant (either KRAS or NRAS tumor gene mutation) colorectal cancer,
Broad match: KRAS mutation (unspecified)Cancer Colorectal
-
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
avutometinib (VS-6766)avutometinib (VS-6766) and Defactinib
Known KRAS or BRAF mutation
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, KRAS Activating Mutation
-
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Cetuximab
…ectum with metastases (metastatic colorectal cancer), primarily non-resectable, confirmed RAS mutations proven in the primary tumor or metastasis (KRAS ans NRAS exon 2, 3, 4)
Broad match: KRAS mutation (unspecified)Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
-
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
CobimetinibHydroxychloroquineAtezolizumab
…une Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Broad match: KRAS mutation (unspecified)Gastrointestinal Cancer
-
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
RigosertibNivolumab
…ma (AJCC version 8) with mutation analysis by next generation sequencing (NGS) confirming KRAS mutation either at time of diagnosis or at progression on first line treatment.
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV
-
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Selinexor 100 mgDocetaxelPembrolizumabFOLFIRISelinexor 40 mgSelinexor 80 mg
Arm B: For patients with RAS mutant CRC, 1-2 prior lines of systemic treatments, and no prior anti- programmed cell death pro…
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
-
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
dabrafenib and trametinib
…l origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation detected in a Clinical Laboratory Improvement Amendments (CLIA)-certified or US Food and …
Broad match: KRAS mutation (unspecified)Thyroid Cancer
-
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
NeratinibDivalproex Sodium
Phase 2 - Dose Expansion Phase: One of the following advanced solid tumors that is RAS-mutated and has progressed during or after treatment with at least one approved therapy or for wh…
Broad match: KRAS mutation (unspecified)Solid Tumor, Adult
-
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
RegorafenibUGT1A1 genotyping (TA6/TA6)UGT1A1 genotyping (TA6/TA7)UGT1A1 genotyping (TA7/TA7)Leucovorin and 5-FU
… made per investigator's routine treatment practice to prescribe regorafenib as 3rd line (RAS mutant) or 4th line (RAS wild type) therapy
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Telaglenestat (CB-839)Palbociclib Oral Capsule or Tablet [Ibrance]
Part 2, Cohort 1: Incurable/locally advanced or metastatic KRAS-mutant CRC previously treated with systemic therapy (examples include: oxaliplatin-, irinotecan-…
Broad match: KRAS mutation (unspecified)Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
-
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
SHR-1210ApatinibPemetrexedCarboplatin
4. confirmes by the central laboratory as KRAS gene mutation
Broad match: KRAS mutation (unspecified)NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect
-
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
PanitumumabIrinotecanFolinic acid5-FU
RAS mutation determined by the local pathology
Broad match: KRAS mutation (unspecified)Treatment Related Cancer
-
Nalirinox Neo-pancreas RAS Mut ctDNA Study
NALRINOX combination
A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treate…
Broad match: KRAS mutation (unspecified)Resectable Pancreatic Ductal Adenocarcinoma
-
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
BinimetinibPalbociclibTrifluridine and Tipiracil Hydrochloride
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
-
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
RMC-4630CobimetinibDrug: Osimertinib
…0 + Cobimetinib only - Participants must have one of the following genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations
Broad match: KRAS mutation (unspecified)Solid Tumor
-
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
THOR-707Checkpoint inhibitoranti-EGFR antibody
Caution: Cohort D only patients with KRAS mutant colon cancer have not typically benefitted from the addition of cetuximab in earlier line…
Broad match: KRAS mutation (unspecified)Metastasis
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
CyclophosphamideFludarabineAldesleukinanti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)
…ia in Solid Tumors v1.1 criteria), metastatic, or unresectable malignancy expressing G12D mutated KRAS as assessed by one of the following methods: Reverse Transcription Polymerase Chain React…
Broad match: KRAS mutation (unspecified)Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer
-
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
OnvansertibBevacizumabFOLFIRI
Documentation of a KRAS mutation in exon 2, 3 or 4 in primary tumor or metastasis, assessed by a Clinical Laboratory Impro…
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer, KRAS Gene Mutation
-
Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
BevacizumabmFOLFOX6 regimenmOXXEL regimenValproic acidCapecitabine5-fluorouracil
RAS mutations
Broad match: KRAS mutation (unspecified)Ras-mutated Metastatic Colorectal Cancer
-
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
DabrafenibTrametinib
No history of malignancy with confirmed activating RAS mutation at any time.
Broad match: KRAS mutation (unspecified)Melanoma, Brain Metastases
-
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
Capecitabine
Assessment of KRAS mutation positivity on surgical sample
Broad match: KRAS mutation (unspecified)Pseudomyxoma Peritonei
-
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Trametinib 0.5 mgTrametinib 1 MGTrametinib 1.5 MGTrametinib 2 mgPonatinib 15 MGPonatinib 30 MG
KRAS mutation
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, KRAS Gene Mutation
-
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
SelinexorDocetaxel
Molecular identification of a KRAS mutation (codons 12, 13, or 61 mutations detected by sequencing) by a CLIA-certified assay (source…
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer
-
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
MethotrexateRegorafenib
Documentation of pathogenic KRAS mutation
Broad match: KRAS mutation (unspecified)KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
-
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
IrinotecanOxaliplatinFloxuridine
Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it)
Broad match: KRAS mutation (unspecified)Colo-rectal Cancer, Liver Metastases
-
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
PDR001
…ith histologically or cytologically confirmed, stage IV or recurrent NSCLC that carries a KRAS/NRAS mutation or no actionable mutation, which are identified by NGS.
Broad match: KRAS mutation (unspecified)Cancer, Lung Cancer Metastatic, Immunotherapy
-
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
AvelumabBinimetinibTalazoparib
Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or oth…
Broad match: KRAS mutation (unspecified)Pancreatic Cancer
-
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
binimetinibnivolumabipilimumab
RAS mutation per local assay at any time prior to Screening or by the central laboratory.
Broad match: KRAS mutation (unspecified)MSS, RAS-mutant Colorectal Cancer
-
Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC
Durvalumab, Tremelimumab and ,FOLFOX
Histologically confirmed diagnoses of colorectal cancer with positive mutated KRas.
Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic
-
Study of MEK162 for Children With Low-Grade Gliomas
MEK162
…GG in a patient with NF1, and any other tumor with a documented activating BRAF, NRAS, or KRAS mutation.
Broad match: KRAS mutation (unspecified)Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
-
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer
Analysis of surgical specimens showed KRAS mutations and positive immunohistochemical staining of PD-L1
Broad match: KRAS mutation (unspecified)Pancreatic Cancer
-
Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
Sapanisertib
…tologically or cytologically confirmed stage IV or recurrent squamous cell lung cancer or KRAS mutant lung cancer that harbors any of the NFE2L2 mutations or KEAP1 mutations
Broad match: KRAS mutation (unspecified)Recurrent Lung Squamous Cell Carcinoma, Stage IV Lung Squamous Cell Carcinoma AJCC v7
-
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
regorafenib
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
Broad match: KRAS mutation (unspecified)Advanced Colorectal Cancer
-
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
E6201
Phase 1: Confirmed relapsed or refractory AML with a documented FLT3 and/or Ras mutation, or ≥ 60 years with newly diagnosed FLT3+ and/or Ras+ AML and not eligible for standard i…
Broad match: KRAS mutation (unspecified)AML, MDS, CMML
-
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
FOLFOXIRI + BevacizumabFOLFOXIRI
…rst-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
AfatinibSelumetinibDocetaxel
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Carcinoma, Non-Small-Cell Lung
-
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
CapecitabineTemozolomideIrinotecanFluorouracilLeucovorin
…y confirmed adenocarcinoma of the colon and/or rectum, with MGMT promoter methylation and RAS mutation.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
BVD-523
Positive for RAS mutation at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory prior to stud…
Broad match: KRAS mutation (unspecified)Acute Myelogenous Leukemia, Myelodysplastic Syndrome
-
Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy
docetaxel plus selumetinib
Patients with MEK signature, RAS mutation or amplification through the VIKTORY trial.
Broad match: KRAS mutation (unspecified)Gastric Adenocarcinoma
-
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
AuranofinSirolimus
Histologic or cytologic confirmation of lung cancer (squamous, ras-mutated adenocarcinoma or small cell lung cancer)
Broad match: KRAS mutation (unspecified)Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
-
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Lapatinibtrametinib
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
DacomitinibPD-0325901Docetaxel
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
Positive for KRAS mutation or Squamous cell histology
Broad match: KRAS mutation (unspecified)KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer
-
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Refametinib (BAY86-9766)
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Broad match: KRAS mutation (unspecified)Carcinoma, Hepatocellular
-
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
defactinib (VS-6063)
Molecular characterization of the tumor demonstrating a KRAS mutation by a CLIA-certified assay.
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, Lung Cancer
-
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Akt Inhibitor GSK2141795Trametinib
Positive for RAS mutation (neuroblastoma RAS viral \[v-ras\] oncogene homolog \[NRAS\] codon 12, 13, 61 mutation or…
Broad match: KRAS mutation (unspecified)Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
-
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
BortezomibAcyclovir
Documented KRAS mutation
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer
-
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Refametinib (BAY86-9766)Sorafenib (BAY43-9006)
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Broad match: KRAS mutation (unspecified)Carcinoma, Hepatocellular
-
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
PimasertibDacarbazine
…ally confirmed, locally advanced or metastatic cutaneous melanoma (stage III c or M1ac) N-Ras mutated.
Broad match: KRAS mutation (unspecified)N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
-
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Sorafenib and irinotecan combinationSorafenib monotherapyIrinotecan monotherapy
Confirmation of KRAS mutation in codons 12 or 13 in the primary tumor or metastases
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
-
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
Adaptive autologous cell immunotherapy
When tumor has a mutated Kras, prior treatment with EGFR antibodies is not mandatory;
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
BKM120Panitumumab
Note: Archival tumour samples are acceptable for K-Ras mutation analysis.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Necitumumab
…cumented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that have not responded to standard therapy or for which no standard therapy is availabl…
Broad match: KRAS mutation (unspecified)Solid Tumors
-
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
NecitumumabGemcitabineCisplatin
…cumented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available
Broad match: KRAS mutation (unspecified)Malignant Solid Tumor
-
Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
linifanib
… II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas
Broad match: KRAS mutation (unspecified)Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
-
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
LenvatinibLenvatinib matched placeboBSC
Participants with ALK positive NCSLC or participants with KRAS mutations were not required to have prior treatment with erlotinib or gefitinib
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer
-
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
SimtuzumabLeucovorinIrinotecanFluorouracil
Metastatic colorectal carcinoma with KRAS mutation
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
CetuximabCisplatinS-1
… standardized epidermal growth factor receptor (EGFR) expression and Kirsten-rat sarcoma (KRAS) mutation assessments
Broad match: KRAS mutation (unspecified)Gastric Cancer
-
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
IPI-504Everolimus
Pathological diagnosis of KRAS mutation positive NSCLC - Stage IIIB or IV
Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer
-
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
4SC-201(Resminostat)FOLFIRI
K-ras mutation (which contraindicates EGFR inhibitor therapy, results from local pathology will be accep…
Broad match: KRAS mutation (unspecified)Advanced Colorectal Carcinoma
-
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ARQ 197 plus erlotinibPemetrexed, docetaxel or gemcitabine
…rlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Broad match: KRAS mutation (unspecified)Metastatic Non-Small Cell Lung Cancer
-
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
GSK1120212docetaxel
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
Broad match: KRAS mutation (unspecified)Lung Cancer, Non-Small Cell
-
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Cetuximab
Histological confirmed colorectal cancer (CRC) with mutated K-RAS and favorable genotypes (any H in FcγRIIa-131).
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms
-
Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer
Gemcitabine and UFTE chemotherapy
K-ras mutant or economical problems)
Broad match: KRAS mutation (unspecified)Metastatic or Recurrent Colorectal Cancer, Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan, Salvage Chemotherapy
-
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
MK-2206 + AZD6244
Results of KRAS (Kirsten-Ras) mutation analysis must be available prior to patient enrollment.
Broad match: KRAS mutation (unspecified)Colorectal Neoplasms
-
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
EverolimusEverolimus
Patients with KRAS-mutation in their primary tumour or metastasis.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
JI-101Everolimus
…y or cytologically confirmed metastatic/advanced ovarian carcinoma or metastatic/advanced KRAS mutant colorectal cancer or metastatic/advanced Head and neck squamous cell cancer (HNSCC) that …
Broad match: KRAS mutation (unspecified)Cancer, Neuroendocrine, Ovarian Cancer, Colon Cancer
-
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
PimasertibFOLFIRI
Histologically confirmed K-Ras mutated colon/rectum cancer
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)
cetuximab/irinotecan/simvastatin
Ras mutation (+) (checked at the central lab)
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
AZD6244ErlotinibAZD6244 + Erlotinib
…all Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Carcinoma
-
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
PemetrexedGemcitabine
KRAS mutation in primary tumour or metastasis.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
cetuximabsimvastatin
…tin-, fluorouracil (5-FU)-, and irinotecan-containing regimens AND have the presence of a k-ras mutation within codon 12, 13, or 61
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
panitumumabsimvastatin
Safety and Efficacy of the Addition of Simvastatin to Panitumumab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II St…
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
chemotherapy and GI-4000GI-4000
…istologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a Ras mutation
Broad match: KRAS mutation (unspecified)Colon Cancer
-
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Panitumumaboxaliplatingemcitabine
Screening for tumor Kras and Braf mutations requires formalin fixed paraffin embedded tumor blocks from core needle excisional biopsy…
Broad match: KRAS mutation (unspecified)Biliary Tract Cancer, Gallbladder Cancer
-
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Birinapant
…horts: Subjects have advanced colorectal cancer that had been previously determined to be KRAS mutant.
Broad match: KRAS mutation (unspecified)Cancer
-
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
bevacizumabtegafur-gimeracil-oteracil potassium
KRAS-mutated
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
PD-0332991
Metastatic colorectal cancer that harbors the Kras or BRAF mutation (15-30 enrollment slots) C.
Broad match: KRAS mutation (unspecified)Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
-
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
Lead-In RidaforolimusComparator: Blinded RidaforolimusComparator: Blinded Placebo
…-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer
-
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
Nexavar (Sorafenib) and irinotecan (Campto)
Patient having a mutated KRAS on 12 or 13 codons on the primary tumour or a metastasis
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
IrinotecanTemsirolimus
KRAS mutation detected by DxS kit in primary tumor or metastatic lesion.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
REOLYSIN®CarboplatinPaclitaxel
…s, as defined by EGFR activating mutations in exons 18 to 21, EGFR FISH amplification, or K-ras mutations in exon 2 (codons 12,13,61).
Broad match: KRAS mutation (unspecified)Carcinoma, Non-small Cell Lung
-
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
fluorouracilleucovorin calciumvorinostat
no prior cetuximab therapy is required for KRAS mutant tumors
Broad match: KRAS mutation (unspecified)Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
-
External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
capecitabinesorafenib tosylate
Tumor with K-ras gene mutation as assessed locally
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
AZD6244docetaxel
Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon enrolment to ship to AZ appointed central l…
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer
-
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
AMG 655AMG 479
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
cetuximablenalidomide
Confirmed K-RAS mutant tumor
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NKTR-102irinotecan
tumor with k-ras mutation
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
GI-4000
Confirmed product related ras mutation
Broad match: KRAS mutation (unspecified)NSCLC
-
Study of Salirasib to Treat Non-Small Cell Lung Cancer
Salirasib
OR previously treated with recurrent disease and documented KRAS mutation
Broad match: KRAS mutation (unspecified)Carcinoma, Non-Small-Cell Lung
-
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
GI-4000Gemcitabine
Patients with non-metastatic pancreas cancer post-resection that have a product-related ras mutation
Broad match: KRAS mutation (unspecified)Pancreas Cancer
-
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
anti-thymocyte globulinfilgrastimbusulfancyclophosphamidemethylprednisolone
Clonal abnormalities (e.g., monosomy 7 or RAS mutations)
Broad match: KRAS mutation (unspecified)Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
-
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
aldesleukinras peptide cancer vaccinesargramostimDetoxPC
Ras mutations must be one of the following point mutations at codon 12:
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
-
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
aldesleukinmutant p53 peptide pulsed dendritic cell vaccineras peptide cancer vaccinesargramostimtherapeutic autologous lymphocytestherapeutic tumor infiltrating lymphocytes
… expressing mutant p53 or ras, e.g.: Lung Pancreatic Breast Colon Cervical Ovarian p53 or ras mutation by point mutation, insertion, or deletion in protein-coding sequence Tumor tissue require…
Broad match: KRAS mutation (unspecified)Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer
-
TCR1020-CD8 T Cells in KRAS-mutated Cancers
TCR1020-CD8 T cells
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Broad match: KRAS mutation (unspecified)Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer
-
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
PF-07985045GemcitabineNab-paclitaxelCetuximabFluorouracilOxaliplatin
Documentation of mutated KRAS gene
Broad match: KRAS mutation (unspecified)Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
-
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
BGB-3245Panitumumab
…ccording to the group they are enrolled into: Group 1: Participants with CRC that harbors KRAS or NRAS mutations in the archival tumor sample or fresh tumor biopsy.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
-
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
IX001 TCR-T cells
…001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, Colorectal Cancer
-
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor
YK0901 cells
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
A Study of YL-17231 in Patients With Advanced Solid Tumors
YL-17231
…vanced or metastatic solid tumors diagnosed histologically and genomically confirmed with KRAS mutation, excluding patients with a clear KRAS wild-type test report in the case of pancreatic can…
Broad match: KRAS mutation (unspecified)Advanced Solid Tumor
-
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
IK-595
KRASmut solid tumors, including but not limited to NSCLC, pancreatic carcinoma, and CRC
Broad match: KRAS mutation (unspecified)Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
-
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
BMF-219
…d/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
-
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
BBP-398 with nivolumab
…ocumented, locally advanced and unresectable, or metastatic NSCLC with documentation of a KRAS mutation within the 1 year prior to screening.
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, Solid Tumor
-
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
RMC-4630LY3214996
Part A: Histological or cytological proof of advanced KRASm NSCLC, CRC or PDAC
Broad match: KRAS mutation (unspecified)Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, KRAS Mutation-Related Tumors
-
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
PRT3645
KRAS-mutant or SMARCA4 loss NSCLC
Broad match: KRAS mutation (unspecified)Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma
-
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
chidamidecelecoxib
For K-ras mutant tumor, antiangiogenic therapy must have been done.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
BI 3011441
…AS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation based on local test.
Broad match: KRAS mutation (unspecified)Solid Tumors, KRAS Mutation
-
PF-07284892 in Participants With Advanced Solid Tumors
PF-07284892lorlatinibbinimetinibcetuximabencorafenib
…or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor.
Broad match: KRAS mutation (unspecified)Solid Tumor
-
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Futibatinib and Binimetinib
…ologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2)
Broad match: KRAS mutation (unspecified)Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
-
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
ELI-002 2P
KRAS/NRAS mutated (G12D or G12R) solid tumor
Broad match: KRAS mutation (unspecified)Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
-
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
BI 1701963BI 3011441
Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening.
Broad match: KRAS mutation (unspecified)Solid Tumors, KRAS Mutation
-
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
FT538CyclophosphamideFludarabineMonoclonal antibody - Dose EscalationMonoclonal antibody - Dose Expansion
Cohort C: CRC having progressed following prior cetuximab treatment or has KRAS/NRAS mutation
Broad match: KRAS mutation (unspecified)Solid Tumor, Adult
-
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
SPYK04
Patients with MAPK pathway alterations positive solid tumor (i.e., BRAF, K/N/H-RAS mutations)
Broad match: KRAS mutation (unspecified)Locally Advanced or Metastatic Solid Tumors
-
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
BI 1701963Camptosar®
Patient must have a confirmed activating KRAS mutation in CRC tumour tissue by local test.
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (CRC)
-
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
a CDK4 / 6 inhibitor and a MEK inhibitor
Patients with advanced KRAS mutation or metastatic digestive system tumor confirmed by histology or cytology and imaging diagn…
Broad match: KRAS mutation (unspecified)Digestive System Tumors
-
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
BBP-398 (Formerly known as IACS-15509)
…ble standard of care or curative therapies (MAPK-pathway alterations include, for example KRASG12C mutant, EGFR-mutant).
Broad match: KRAS G12CTumor, Solid
-
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
Brimarafenib
For participants with KRAS mutations, tumor types of colorectal cancer (CRC) and pancreatic cancer were excluded.
Broad match: KRAS mutation (unspecified)Solid Tumor, B-Raf Mutation-Related Tumors
-
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
LNP3794
Pathologically documented, locally-advanced or metastatic solid malignancy with NRAS or KRAS mutation
Broad match: KRAS mutation (unspecified)NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
-
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
HL-085Docetaxel
KRAS mutation NSCLC.
Broad match: KRAS mutation (unspecified)Nsclc
-
Study of FCN-437c in Patients With Advanced Solid Tumors
FCN-437
KRAS mutant NSCLC confirmed by a documented historical report
Broad match: KRAS mutation (unspecified)Solid Tumor, Adult
-
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
BinimetinibHydroxychloroquine
… from any Clinical Laboratory Improvement Act (CLIA) certified laboratory demonstrating a KRAS mutation.
Broad match: KRAS mutation (unspecified)Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
-
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
MivavotinibPaclitaxel
…cy, including but not limited to high-grade epithelial ovarian cancer or cancer harboring K-RAS mutation, either refractory to standard therapy or for which no effective standard therapy is avai…
Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
-
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
NBF-006
…histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment availa…
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
-
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
COM701COM701 with Opdivo (Nivolumab).
CRC (microsatellite stable, KRAS mutation) - P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort.
Broad match: KRAS mutation (unspecified)Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
-
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
RO5126766
Documented presence of KRAS mutation
Broad match: KRAS mutation (unspecified)Advanced Non-small Cell Lung Cancer
-
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
TrametinibRuxolitinib
Patients with histological diagnosis of RAS mutant advanced colorectal and pancreatic adenocarcinoma having received at least 1 prior line o…
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Adenocarcinoma
-
A Study of ASN007 in Patients With Advanced Solid Tumors
ASN007: ascending dosesASN007 RD
Group 3: KRAS mutant CRC.(Part B)
Broad match: KRAS mutation (unspecified)Cancer, Malignancy, Neoplasia, Neoplasm
-
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
TrametinibTrifluridine and Tipiracil Hydrochloride
Documented RAS-mutated tumor without activating PIK3CA mutations or PTEN mutation (loss of PTEN or silencing)
Broad match: KRAS mutation (unspecified)Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation
-
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
PembrolizumabTrametinib
for expansion cohorts, patient's tumor must also harbor a KRAS mutation detected in a CLIA certified laboratory
Broad match: KRAS mutation (unspecified)KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
-
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
ompenaclidFOLFIRIBevacizumabFOLFOX regimen
…r the expansion stage only, patients must have a tumor that is laboratory-confirmed to be RAS mutant.
Broad match: KRAS mutation (unspecified)Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
-
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
BinimetinibPemetrexedCisplatin
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Broad match: KRAS mutation (unspecified)Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation, Lung Cancer
-
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
EverolimusNeratinibPalbociclibTrametinib
…mors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification
-
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
AZD4785
…nts must have histological or cytological confirmation of a solid tumour known to harbour KRAS mutations (e.g., NSCLC, mCRC, pancreatic or cholangiocarcinoma), and have progressed despite standa…
Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer, Advanced Solid Tumours
-
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
HM95573, cobimetinibHM95573, cetuximabHM95573, cobimetinibHM95573, cetuximab
KRAS-mutant NSCLC
Broad match: KRAS mutation (unspecified)Locally Advanced Solid Tumor, Metastatic Solid Tumor
-
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
BinimetinibPalbociclib
Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any CLIA-certified method) for which curable treatment modalities are not an option
Broad match: KRAS mutation (unspecified)Lung Cancer
-
First-in-Human Study of KO-947 in Non-Hematological Malignancies
KO-947
Malignancy of non-squamous histology that carries a BRAF, KRAS, NRAS or HRAS mutation(s).
Broad match: KRAS mutation (unspecified)Advanced Malignant Neoplasm
-
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
HM95573
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
Broad match: KRAS mutation (unspecified)Solid Tumor
-
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
ABBV-621VenetoclaxBevacizumabFOLFIRI
…n cohorts must have metastatic or advanced unresectable colorectal cancer with documented RAS mutations (as determined by local testing).
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors, Cancer, Hematologic Malignancies
-
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
ribociclibTrametinib
Advanced or metastatic KRAS-mutant CRC who have failed at least two prior systemic antineoplastic therapies in the advanced …
Broad match: KRAS mutation (unspecified)Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
-
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
LY3214996MidazolamAbemaciclibNab-paclitaxelGemcitabineEncorafenib
…tion) and advanced, unresectable, or metastatic non-small cell lung cancer with a BRAF or RAS mutation, or NRAS mutant melanoma (dose expansion).
Broad match: KRAS mutation (unspecified)Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
-
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
MEK162 and mFOLFIRI
Patients with histologically confirmed RAS (HRAS, NRAS, or KRAS) positive metastatic colorectal cancer.
Broad match: KRAS mutation (unspecified)Advanced KRAS Positive Metastatic Colorectal Cancer
-
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
LXH254PDR001
Patients with confirmed KRAS-mutated NSCLC
Broad match: KRAS mutation (unspecified)NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
-
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
CCT3833
Documented presence of either BRAF or RAS mutations, as established by validated mutation testing from tumour biopsy.
Broad match: KRAS mutation (unspecified)Melanoma, Cancer
-
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
CC-90003
…hibitor, in Subjects With Locally-Advanced or Metastatic, Relapsed, or Refractory BRAF or RAS-Mutated Malignancies
Broad match: KRAS mutation (unspecified)Neoplasm Metastasis
-
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
MM-151MM-121MM-141trametinib
Patients must have either heregulin-positive cancer, cancer with RAS mutation, IGF-1 positive cancer, or RAS wild type cancer.
Broad match: KRAS mutation (unspecified)Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
-
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
Momelotinib (MMB)Trametinib
Individuals with KRAS-mutated metastatic or recurrent non-small cell lung cancer
Broad match: KRAS mutation (unspecified)Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
-
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
Palbociclib + Taselisib / Pictilisib
KRAS mutations) may be considered, depending on emerging preclinical and clinical data on these novel an…
Broad match: KRAS mutation (unspecified)Advanced Solid Tumours, Breast Cancer
-
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
BGB-283
We simultaneously require patients with one of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
Broad match: KRAS mutation (unspecified)Solid Tumors
-
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
CobimetinibCobimetinibOnartuzumabVemurafenib
Patients with a histologically confirmed, KRAS-mutant, Stage IV colorectal adenocarcinoma, or KRAS-mutant metastatic non-small-cell lung carcin…
Broad match: KRAS mutation (unspecified)Neoplasms
-
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
PalbociclibPD-0325901
…escalation/MTD cohorts, participants must have histologically confirmed malignancy with a RAS mutation that is metastatic or unresectable and for which standard curative or palliative measures…
Broad match: KRAS mutation (unspecified)KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
-
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
MEK inhibitor MEK162idarubicincytarabine
Confirmed RAS mutation (NRAS or KRAS) or confirmed PTPN11 mutation, measured on peripheral blood or bone marrow …
Broad match: KRAS mutation (unspecified)Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
-
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Birabresib
…on-small cell lung cancer harboring a rearranged ALK gene/fusion protein (FISH or IHC) or KRAS mutation (as defined by any molecular analysis);
Broad match: KRAS mutation (unspecified)NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
-
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
CB-5083
Phase 1b Dose Expansion RAS Mutated mCRC Arm only - Histologically confirmed colorectal cancer with a K-RAS or N-RAS mutation…
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors
-
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
BGB-283
One of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
Broad match: KRAS mutation (unspecified)Solid Tumors
-
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
CarboplatinPaclitaxelTrametinib
Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (any G12, G13, Q61) confirmed by Clinical Laboratory Improvement Act (CLIA)-certified tes…
Broad match: KRAS mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
-
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
MEK162Erlotinib
Have a tissue or blood proven KRAS or EGFR mutation confirmed in a Clinical Laboratory Improvement Amendments (CLIA)certified lab (only requi…
Broad match: KRAS mutation (unspecified)Lung Cancer, Non-Small Cell Lung Cancer
-
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
VS-6766Everolimus
In Part IIC at least three patients should have KRAS mutant lung cancer.
Broad match: KRAS mutation (unspecified)Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
-
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
PaclitaxelCarboplatinSelumetinibPemetrexedCisplatin
Although KRAS mutation is not mandatory, patients accrued to the RP2D expansion cohorts will have a sample sent …
Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer
-
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
CobimetinibMEHD7945A
Locally advanced or metastatic solid KRAS-mutant tumors, for which standard therapies do not exist, have proven ineffective or intolerable…
Broad match: KRAS mutation (unspecified)Neoplasms
-
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
trametinibfluorouracil
Presence of KRAS gene mutation (at codon 12, 13, or 61) for patients on expansion cohort.
Broad match: KRAS mutation (unspecified)Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
-
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
recombinant albumin fusion protein sEphB4-HSA
For expansion Cohort B: Advanced pathologically proven mutant KRAS non-small cell lung cancer (group 1), pancreatic cancer (group 2
Broad match: KRAS mutation (unspecified)Unspecified Adult Solid Tumor, Protocol Specific
-
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
selumetinibcetuximab
In the MTD expansion cohort: Patients must have biopsy proven K-RAS mutant, metastatic colorectal cancer that has progressed on at least 2 prior standard therapies
Broad match: KRAS mutation (unspecified)Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
-
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
MSC1936369B (pimasertib)SAR245409 (PI3K and mTOR inhibitor)MSC1936369B (pimasertib)SAR245409 (PI3K and mTOR inhibitor)
Relapsed or refractory metastatic colorectal cancer (CRC) with dual KRAS and PIK3CA mutation with no approved therapies, or
Broad match: KRAS mutation (unspecified)Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
-
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
MEK162 + RAF265
The patients' tumors must contain documented activating somatic BRAFV600E\* , NRAS or KRAS mutations (except for pancreatic cancer)
Broad match: KRAS mutation (unspecified)Advanced Solid Tumors
-
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
CetuximabAZD6244
In the MTD expansion cohort: Patients must have biopsy proven K-RAS mutant, metastatic colorectal cancer that has progressed on at least 2 prior standard therapies.
Broad match: KRAS mutation (unspecified)Colonic Neoplasms, Cancer of the Colon, Colon Cancer, Colon Neoplasms
-
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
PF-05212384PD-0325901PF-05212384irinotecan
For patients enrolled in Stage 1 of Arm D, tumors with KRAS or BRAF mutation (archived or fresh biopsy).
Broad match: KRAS mutation (unspecified)Advanced Cancer
-
Monotherapy Dose Finding With BI 847325 in Solid Tumours
day 1 to day 5day 1 to day 14
…rine pancreas adenocarcinoma, and have been shown on their archival tumour sample to have KRAS or BRAF mutation.
Broad match: KRAS mutation (unspecified)Neoplasms
-
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
GDC-0623
… cohort must have had no more than four prior systemic therapies for cancer and must have KRAS mutant CRC (Stage II A and B), pancreatic cancer (Stage IIC, or KRAS mutant NSCLC \[Stage IID\])
Broad match: KRAS mutation (unspecified)Solid Cancers
-
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Resistance to Erbitux: patients with Ras mutations, or for whom Erbitux has failed (if tumor advanced either immediately or within 3 months…
Broad match: KRAS mutation (unspecified)Carcinoma, Colorectal
-
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
REOLYSIN®IrinotecanLeucovorinFluorouracil (5-FU)Bevacizumab
…y of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Broad match: KRAS mutation (unspecified)KRAS Mutant Metastatic Colorectal Cancer
-
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
CS-1008FOLFIRI
KRAS Mutant
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
sorafenib
…logically confirmed, advanced (stage IIIB with pleural effusion, stage IV, or recurrent), kras mutation positive, non-small cell lung cancer (NSCLC)
Broad match: KRAS mutation (unspecified)Carcinoma, Non Small Cell Lung
-
SORAVE - Sorafenib and Everolimus in Solid Tumors
Combination of sorafenib and everolimus
…th solid tumors relapsed after and/or refractory to standard therapy (dose finding part), KRAS mutated NSCLC patients after ≥ 1st relapse for the extension phase
Broad match: KRAS mutation (unspecified)Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer
-
Erlotinib and Temsirolimus for Solid Tumors
ErlotinibTemsirolimus
Patients cannot have KRAS or BRAF mutations.
Broad match: KRAS mutation (unspecified)Solid Tumors
-
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
GSK1120212
CRC must be KRAS or BRAF mutation positive.
Broad match: KRAS mutation (unspecified)Solid Tumours
-
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
RO5083945
histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+ and mutant KRAS colorectal cancer (Part 2);
Broad match: KRAS mutation (unspecified)Neoplasms
-
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
5-FUCetuximabDasatinibLeucovorinOxaliplatin
…2, 13) or sufficient available tumor tissue from the primary tumor or metastatic site for KRAS mutation analysis \[Phase II only\].
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
cetuximaberlotinib hydrochloride
…ional status may be determined either by polymerase chain reaction (PCR) assay (e.g., DxS KRAS mutation kit) or by direct sequencing of KRAS exon 2, codons 12 and 13
Broad match: KRAS mutation (unspecified)Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
-
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
ras peptide cancer vaccinesargramostim
Tumor must demonstrate a specific K-ras mutation at codon 12 for which a vaccine preparation is available
Broad match: KRAS mutation (unspecified)Lung Cancer
-
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
BinimetinibPalbociclib
Patients with verified and operable KRAS-positive mutant lung adenocarcinoma, colorectal, or pancreatic cancer
Broad match: KRAS mutation (unspecified)Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
-
TCR-T Cell Therapy on Advanced Solid Tumors
TCR-T therapy
A Prospective, One Arm Clinical Study on the Safety, Efficacy and Pharmacokinetics of KRAS Mutant Antigen Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.
Broad match: KRAS mutation (unspecified)Pancreatic Cancer
-
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Irradiated Allogeneic Cells
…lastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation
Broad match: KRAS mutation (unspecified)Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
-
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Trifluridine/tipiracil
Depending on RAS status, patients with RAS mutant receive Lonsurf® as 3rd line treatment, those with RAS wild type receive Lonsurf® as 3rd/…
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer
Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation
Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer
-
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
1. positive mutated KRas homogeneous population for EGFR Wild type (WT) patients (exclusive with EGFR mutation)
Broad match: KRAS mutation (unspecified)Carcinoma, Non-Small-Cell Lung
-
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
RegorafenibUGT1A1 genotyping (TA6/TA6)UGT1A1 genotyping (TA6/TA7)UGT1A1 genotyping (TA7/TA7)
Prognostic Value of EGFR Expression, KRAS Mutation and Tumor Sideness in Patients With Metastatic Colorectal Cancer Treated With Regorafenib…
Broad match: KRAS mutation (unspecified)Colorectal Cancer
-
LOTCOL Study: Local Treatment of Colo-rectal Liver Met
Standard Chemotherapy
Progressive disease on or within 4 months after 1.line chemotherapy for KRAS mutant or after 2.line chemotherapy in KRAS wild type patients
Broad match: KRAS mutation (unspecified)Metastatic Colo-rectal Cancer
No trials match these filters.